Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151213 | 0.82 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL25434306 | 0.82 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL27753904 | 0.82 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| Ammonia Solution, Strong SCHEMBL4268652 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL27731704 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL31658961 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA4 | |
| Bromide SCHEMBL28158222 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL308029 | 0.78 | MAPT (0.43) | SMN1; SMN2CA12CA1CA2CA4 | |
| Bromide SCHEMBL1307432 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL8375522 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751880-A | Modified fluorosilicone polymer, two-component silicone sealant and preparation method thereof | 广州白云科技股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119751877-A | Modified fluorosilicone cross-linking agent, double-component silicone sealant and preparation method thereof | 广州白云科技股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| EP-1225194-B2 | Method of forming a dielectric interlayer film with organosilicon precursors | AIR PROD & CHEM (US) | 2013-09-18 | — | — | EP | claimed |
| EP-1225194-B1 | Method of forming a dielectric interlayer film with organosilicon precursors | AIR PROD & CHEM (US) | 2008-10-01 | — | — | EP | claimed |
| US-6583048-B2 | Chemical vapor deposition from a silyl ether, a silyl ether oligomer, or an organosilicon compound containing one or more reactive groups, to form an interlayer dielectric film having a dielectric constant of 3.5 or less. | AIR PRODUCTS AND CHEMICALS, INC. | 2003-06-24 | — | — | US | claimed |
| US-20020142579-A1 | ORGANOSILICON PRECURSORS FOR INTERLAYER DIELECTRIC FILMS WITH LOW DIELECTRIC CONSTANTS | VERSUM MATERIALS US, LLC | 2002-10-03 | — | — | US | claimed |
| EP-1225194-A2 | Method of forming a dielectric interlayer film with organosilicon precursors | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2002-07-24 | — | — | EP | claimed |
| US-20260128377-A1 | ELECTROLYTE WITH HIGH LIFSI CONCENTRATION | ARKEMA FRANCE (FR) | 2026-05-07 | — | — | US | disclosed |
| EP-4716967-A1 | ELECTROLYTE WITH HIGH LIFSI CONCENTRATION | ARKEMA France (FR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4703405-A1 | CRYSTALLINE POLYOXYALKYLENE-BASED POLYMER AND CURABLE COMPOSITION COMPRISING SAME | Kaneka Corporation (JP) | 2026-03-04 | — | — | EP | disclosed |
| EP-3950832-B1 | CURABLE COMPOSITION AND CURED PRODUCT | KANEKA CORP (JP) | 2025-10-22 | — | — | EP | disclosed |
| EP-3889206-B1 | POLYOXYALKYLENE POLYMER AND CURABLE COMPOSITION | KANEKA CORP (JP) | 2025-10-15 | — | — | EP | disclosed |
| EP-4596622-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-1195397-A1 | Composition of cyclic olefin addition copolymer and cross-linked material | JSR Corporation (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-6303728-B1 | REACTING SILICON HYDRIDE COMPOUND, E.G., DICHLOROMETHYLSILANE WITH AN ALKENYL GROUP-CONTAINING COMPOUND, E.G., ALLYL-TERMINATED POLYISOBUTYLENE; CATALYST OF A GROUP VIII METAL-CONTAINING CATALYST AND A SULFUR COMPOUND | KANEKA CORPORATION (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6121379-A | Processes for producing polymers having functional groups | KANEKA CORPORATION (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-1000951-A1 | HYDROSILYLATION PROCESS AND POLYMERS PRODUCED BY THE PROCESS | KANEKA CORPORATION (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-5998509-A | BLEND OF AN EPOXY RESIN, POLYSILOXANE CURING AGENT AND FILLER | KABUSHIKI KAISHA TOSHIBA (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0864588-A1 | PROCESSES FOR PRODUCING POLYMERS HAVING FUNCTIONAL GROUPS | KANEKA CORPORATION (JP) | 1998-09-16 | — | — | EP | disclosed |
| EP-0212063-B1 | URETHANE RESINS CONTAINING HYDROLYZABLE MOIETIES FROM ORGANOSILANE COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260128377-A1 | ELECTROLYTE WITH HIGH LIFSI CONCENTRATION | CCNI, FLI1, FOS | SMN1; SMN2 1085/4885CA12 507/4885CA1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.